Company intelligence / Profile preview

Swissaustral Biotech

Monthey, Switzerland

Ownership: Private
Development stage: Other

Overview

Swissaustral develops and commercializes high-performance industrial enzymes derived from extremophilic microorganisms. The company's flagship product, recombinant glutamate dehydrogenase (GDH), is commercialized and used in diagnostic kits for detecting liver and kidney diseases in humans and animals, and for detecting spoiled products in the food industry.

Therapeutic areas: NephrologyGastroenterology
Modalities: Enzyme replacement therapyProtein
Industry: Chemicals & Materials

Partnerships

University of Georgia (research collaboration)Ginkgo Bioworks (enzyme development partnership)Kerafast (distribution partnership)

Beyond the preview

Go deeper on Swissaustral Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swissaustral Biotech.

Explore the full profile